Drug intelligence / Profile preview

68Ga-ST14-06

Development stage: Unknown
Lead developer: Shanghai Jiao Tong University
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals

Overview

68Ga-ST14-06: sourced facts only. name: "ST14-06 emerged as the preferred precursor with experimental inhibition assays confirming its high affinity for ST14 (IC50 = 1.06 ± 0.08 nM)." [PMID:39721147]; target: "ST14-06 emerged as the preferred precursor with experimental inhibition assays confirming its high affinity for ST14 (IC50 = 1.06 ± 0.08 nM)." [PMID:39721147]; developer: "Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 210000, China." [PMID:39721147]; modality: "This study aimed to develop a 68Ga-labeled PET radiopharmaceutical targeting ST14 for pancreatic cancer detection." [PMID:39721147]

Targets

ST14 (Matriptase)

Beyond the preview

Go deeper on 68Ga-ST14-06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 68Ga-ST14-06.